Dyspnea and Reversibility of Antiplatelet Agents: Ticagrelor, Elinogrel, Cangrelor, and Beyond

Publisher： Karger

E-ISSN： 1421-9751|127|1|20-24

ISSN： 0008-6312

Source： Cardiology, Vol.127, Iss.1, 2013-10, pp. : 20-24

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mortality Benefit in PLATO Cannot Be Explained by Antiplatelet Properties of Ticagrelor

By  

Cardiology, Vol. 117, Iss. 3, 2011-01 ,pp. : 231-233

Karger

Access to resources Recommend Favorite

Potential Benefits of Ticagrelor beyond Platelet Inhibition

By  

Cardiology, Vol. 125, Iss. 1, 2013-04 ,pp. : 31-33

Karger

Access to resources Recommend Favorite

Ticagrelor

By  

PRACTICAL DIABETES (INCORPORATING CARDIABETES), Vol. 33, Iss. 7, 2016-09 ,pp. : 258-259

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor

By De Servi Stefano   Navarese Eliano Pio   D’Urbano Maurizio   Savonitto Stefano  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2117-2122

Informa Healthcare

Access to resources Recommend Favorite

Gastrointestinal Adverse Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive

By  

Cardiology, Vol. 126, Iss. 1, 2013-07 ,pp. : 35-40

Karger

Access to resources Recommend Favorite